

Financial Supervision Authority

Current report no. 59 / 2018

Date prepared: 2018-10-26

Abbreviated name of the issuer:

Mabion S.A.

Subject:

Submission of the second patent application under the MabionMS project

Legal basis

Art.17 item 1 of MAR –confidential information

Content of the report

With reference to Current Report no 56/2017 of 5th of December 2017 concerning the submission of the European patent application for the invention in the field of innovative therapy for treating patients suffering from multiple sclerosis _MS_ using MabionCD20 antibody, the Management Board of Mabion S.A. _"the Issuer"_ informs that on 26th of October 2018 submitted to the Patent Office of the Republic of Poland further patent application, with the possibility of extending in PCT mode, from the area of application of MabionCD20 in treating patients with MS, under the name "Low aggregate anti CD20 ligand formulation."

This is the second patent application in the use of MabionCD20 for the treatment of sclerosis as an innovative indication for the molecule. This application concerns MabionCD20 application on a monotherapy basis.

The Issuer indicates that submitting the application does not mean a guarantee of obtaining patent protection.